Skip to main content
    P

    Phathom Pharmaceuticals Inc (PHAT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.88
    -0.18 (-2.97%)

    Market Cap: $492.63M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Phathom Pharmaceuticals Inc (PHAT) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Phathom Pharmaceuticals reported revenue of $175.11M for the fiscal year ended Dec 31, 2025, up 216.9% from the year before. That year, net income was -$221.25M with a net margin of -126.3%, operating cash flow was -$166.78M and free cash flow was -$167.00M. The quarter ended Sep 30, 2026 had revenue of $84.72M and net income of -$13.90M.

    Revenue and Margins

    The operating margin was -91.4% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$175.11M+216.9%87.1%-91.4%-126.3%
    Dec 2024$55.25M+8001.5%85.6%-502.2%-605.1%
    Dec 2023$682.00KN/A75.5%-24532.6%-29558.9%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$175.11M$55.25M$682.00K$0$0$0$0$0
    Cost of revenue$22.60M$7.97M$167.00K$0$0$0$0N/A
    Gross profit$152.51M$47.28M$515.00K$0$0$0$0N/A
    Research and development$32.78M$34.08M$49.90M$71.44M$72.34M$98.15M$99.27M$20.00K
    Operating income-$159.99M-$277.47M-$167.31M-$172.44M-$135.08M-$125.67M-$106.22M-$1.23M
    Net income-$221.25M-$334.33M-$201.59M-$197.72M-$143.88M-$129.07M-$255.13M-$1.29M
    EBITDA-$156.53M-$274.49M-$165.05M-$169.82M-$133.02M-$123.98MN/A-$50.00K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$84.72M$74.27M$58.30M$57.58M$49.50M$39.50M$28.52M$29.66M$16.35M$7.32M$1.91M$682.00K
    Gross profit$66.36M$59.18M$46.30M$49.94M$43.31M$34.47M$24.80M$25.85M$14.00M$5.95M$1.49M$515.00K
    Operating income-$85.00K-$3.96M-$15.48M-$5.93M-$15.27M-$59.92M-$78.86M-$59.42M-$70.80M-$77.30M-$69.95M-$69.88M
    Net income-$13.90M-$17.58M-$30.37M-$21.15M-$29.97M-$75.81M-$94.32M-$74.45M-$85.58M-$91.45M-$82.85M-$79.57M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $209.74M exceeded cash and equivalents by $79.76M. Shareholder equity was negative, at -$438.17M, as total liabilities of $697.32M exceeded total assets of $259.15M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$259.15M$378.32M$413.84M$164.81M$189.43M$295.11M$257.18M$902.00K
    Current assets$228.97M$360.13M$397.43M$160.51M$186.53M$291.37M$255.60M$902.00K
    Cash and equivalents$129.97M$297.26M$381.39M$155.38M$183.26M$287.50M$243.76M$879.00K
    Total liabilities$697.32M$631.90M$486.60M$239.62M$117.28M$100.84M$29.22M$2.19M
    Short-term debt$648.00K$20.28M$726.00K$708.00K$487.00K$7.35M$0$1.95M
    Long-term debt$209.09M$201.41M$137.84M$95.26M$89.67M$39.63M$22.78M$0
    Shareholder equity-$438.17M-$253.58M-$72.76M-$74.81M$72.16M$194.27M$227.96M-$1.29M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$345.02M$327.07M$305.12M$259.15M$240.29M$250.22M$294.21M$378.47M$387.04M$319.38M$356.50M$413.84M
    Total liabilities$692.66M$671.35M$642.08M$697.32M$662.82M$656.05M$632.58M$632.05M$574.16M$553.21M$505.00M$486.60M
    Cash and equivalents$184.56M$182.48M$180.90M$129.97M$135.16M$149.57M$212.31M$297.26M$334.68M$276.24M$322.23M$381.39M
    Shareholder equity-$347.64M-$344.27M-$336.95M-$438.17M-$422.53M-$405.83M-$338.38M-$253.58M-$187.11M-$233.83M-$148.50M-$72.76M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$166.78M-$266.77M-$137.58M-$146.53M-$148.46M-$69.69M-$36.51M-$1.02M
    Capital expenditures$229.00K$135.00K$1.63M$1.04M$328.00K$1.04M$132.00K$132.00K
    Free cash flow-$167.00M-$266.90M-$139.21M-$147.57M-$148.78M-$70.73M-$36.64M-$1.16M
    Investing cash flow-$229.00K-$135.00K-$1.63M-$1.04M-$328.00K-$1.04M-$25.25M-$25.25M
    Financing cash flow-$288.00K$182.77M$367.58M$120.04M$44.71M$114.46M$304.65M$1.90M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$1.84M-$1.93M-$15.65M-$5.00M-$14.12M-$62.73M-$84.93M-$63.46M-$63.57M-$70.72M-$69.02M-$43.80M
    Capital expenditures$110.00K$44.00K$61.00K$87.00K$27.00K$97.00K$18.00K$5.00K$44.00K$46.00K$40.00K$475.00K
    Free cash flow$1.73M-$1.97M-$15.71M-$5.09M-$14.14M-$62.83M-$84.95M-$63.46M-$63.62M-$70.77M-$69.06M-$44.27M
    Last 12 quarters

    Frequently Asked Questions About PHAT

    What is Phathom Pharmaceuticals' annual revenue?

    Phathom Pharmaceuticals reported revenue of $175.11M for the fiscal year ended Dec 31, 2025.

    How fast is Phathom Pharmaceuticals' revenue growing?

    Revenue was up 216.9% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Phathom Pharmaceuticals profitable?

    No. Phathom Pharmaceuticals reported net income of -$221.25M for the fiscal year ended Dec 31, 2025, with a net margin of -126.3%.

    How much free cash flow does PHAT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$166.78M minus capital expenditures of $229.00K produced free cash flow of -$167.00M.

    How much debt does Phathom Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $209.09M, short-term debt of $648.00K and cash and equivalents of $129.97M.